The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy.

The HIV-1 virus (human immunodeficiency virus) affects 36.9 million people worldwide, with approximately 900000 deaths in 2017. The virus carrier can develop severe immunodeficiency since CD4 T lymphocytes are the main target, leading to acquired immunodeficiency syndrome (AIDS).